tradingkey.logo

Quanterix Corp

QTRX
6.090USD
+0.210+3.57%
Fechamento 02/06, 16:00ETCotações atrasadas em 15 min
284.30MValor de mercado
PerdaP/L TTM

Mais detalhes de Quanterix Corp Empresa

Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.

Informações de Quanterix Corp

Código da empresaQTRX
Nome da EmpresaQuanterix Corp
Data de listagemDec 07, 2017
CEOToloue (Masoud)
Número de funcionários471
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 07
Endereço900 Middlesex Turnpike
CidadeBILLERICA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal01821
Telefone16173019400
Sitehttps://www.quanterix.com/
Código da empresaQTRX
Data de listagemDec 07, 2017
CEOToloue (Masoud)

Executivos da empresa Quanterix Corp

Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Masoud Toloue, Ph.D.
Dr. Masoud Toloue, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
282.30K
-1817.00%
Mr. William P. (Bill) Donnelly
Mr. William P. (Bill) Donnelly
Executive Chairman of the Board
Executive Chairman of the Board
140.51K
+2377.00%
Ms. Karen A. Flynn
Ms. Karen A. Flynn
Independent Director
Independent Director
49.78K
+23372.00%
Mr. Scott Mendel
Mr. Scott Mendel
Director
Director
31.59K
+25316.00%
Dr. Myla P. Lai-Goldman, M.D.
Dr. Myla P. Lai-Goldman, M.D.
Director
Director
30.34K
+25316.00%
Mr. Jeffrey Thomas (Jeff) Elliott
Mr. Jeffrey Thomas (Jeff) Elliott
Lead Independent Director
Lead Independent Director
27.33K
+23372.00%
Ms. Vandana Sriram, CPA
Ms. Vandana Sriram, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.34K
-274.00%
Dr. Ivana Magov Evi-liebisch, J.D., Ph.D.
Dr. Ivana Magov Evi-liebisch, J.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Garret Hampton, Ph.D.
Dr. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Alan Sachs, M.D., Ph.D.
Dr. Alan Sachs, M.D., Ph.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Masoud Toloue, Ph.D.
Dr. Masoud Toloue, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
282.30K
-1817.00%
Mr. William P. (Bill) Donnelly
Mr. William P. (Bill) Donnelly
Executive Chairman of the Board
Executive Chairman of the Board
140.51K
+2377.00%
Ms. Karen A. Flynn
Ms. Karen A. Flynn
Independent Director
Independent Director
49.78K
+23372.00%
Mr. Scott Mendel
Mr. Scott Mendel
Director
Director
31.59K
+25316.00%
Dr. Myla P. Lai-Goldman, M.D.
Dr. Myla P. Lai-Goldman, M.D.
Director
Director
30.34K
+25316.00%
Mr. Jeffrey Thomas (Jeff) Elliott
Mr. Jeffrey Thomas (Jeff) Elliott
Lead Independent Director
Lead Independent Director
27.33K
+23372.00%

Detalhamento da receita

FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q2
FY2024Q1
FY2023
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Product revenue
26.15M
0.00%
Service and other revenue
13.95M
0.00%
Collaboration and license revenue
46.00K
0.00%
Por RegiãoUSD
Nome
Receita
Proporção
North America
24.39M
0.00%
EMEA
11.08M
0.00%
Asia Pacific
4.68M
0.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Product revenue
26.15M
0.00%
Service and other revenue
13.95M
0.00%
Collaboration and license revenue
46.00K
0.00%

Distribuição de ações

Atualizado em: sex, 21 de nov
Atualizado em: sex, 21 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Portolan Capital Management, L.L.C.
9.12%
Columbia Threadneedle Investments (UK)
6.71%
BlackRock Institutional Trust Company, N.A.
6.12%
The Vanguard Group, Inc.
5.73%
Telegraph Hill Partners
5.36%
Outro
66.95%
Investidores
Investidores
Proporção
Portolan Capital Management, L.L.C.
9.12%
Columbia Threadneedle Investments (UK)
6.71%
BlackRock Institutional Trust Company, N.A.
6.12%
The Vanguard Group, Inc.
5.73%
Telegraph Hill Partners
5.36%
Outro
66.95%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
37.10%
Investment Advisor
22.28%
Hedge Fund
12.26%
Individual Investor
6.31%
Private Equity
5.36%
Research Firm
4.36%
Pension Fund
0.44%
Bank and Trust
0.20%
Family Office
0.13%
Outro
11.55%

Participação acionária institucional

Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
383
38.26M
81.91%
-7.44M
2025Q3
384
34.11M
73.41%
-9.53M
2025Q2
391
36.46M
81.18%
-12.95M
2025Q1
401
40.45M
104.19%
-6.42M
2024Q4
388
38.02M
98.63%
-6.28M
2024Q3
386
36.47M
95.03%
-5.94M
2024Q2
394
35.66M
93.20%
-9.57M
2024Q1
395
35.56M
93.43%
-9.17M
2023Q4
388
34.77M
91.99%
-10.35M
2023Q3
382
36.53M
97.35%
-9.84M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Portolan Capital Management, L.L.C.
4.26M
9.12%
+626.23K
+17.23%
Sep 30, 2025
Columbia Threadneedle Investments (UK)
3.14M
6.71%
+8.77K
+0.28%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.86M
6.12%
+212.22K
+8.01%
Sep 30, 2025
The Vanguard Group, Inc.
2.65M
5.67%
+118.56K
+4.69%
Sep 30, 2025
Telegraph Hill Partners
2.50M
5.36%
+2.50M
--
Sep 30, 2025
Walt (David R)
1.86M
3.99%
+2.59K
+0.14%
Oct 01, 2025
Invenomic Capital Management LP
1.39M
2.98%
+248.10K
+21.67%
Sep 30, 2025
William Blair Investment Management, LLC
1.32M
2.82%
+187.30K
+16.60%
Sep 30, 2025
Easterly Investment Partners LLC
1.25M
2.68%
+168.55K
+15.55%
Sep 30, 2025
Millennium Management LLC
1.21M
2.59%
+1.20M
+9880.18%
Sep 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: ter, 2 de dez
Atualizado em: ter, 2 de dez
Nome
Proporção
Invesco NASDAQ Future Gen 200 ETF
0.63%
iShares Micro-Cap ETF
0.04%
Fidelity Enhanced Small Cap ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Biotechnology ETF
0.02%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Value ETF
0.01%
Global X Russell 2000 ETF
0.01%
Ver Mais
Invesco NASDAQ Future Gen 200 ETF
Proporção0.63%
iShares Micro-Cap ETF
Proporção0.04%
Fidelity Enhanced Small Cap ETF
Proporção0.03%
Avantis US Small Cap Equity ETF
Proporção0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.02%
iShares Biotechnology ETF
Proporção0.02%
Proshares Ultra Russell 2000
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0.01%
iShares Russell 2000 Value ETF
Proporção0.01%
Global X Russell 2000 ETF
Proporção0.01%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
KeyAI